DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 minute ago

ISRG·Intuitive Surgical, Inc.

$.
-. (-.%)
After Hours
High
$439.20
Open
$432.22
Market Cap
154.51B
52W High
$603.88
Low
$414.30
P. Close
$418.55
P/E
51.86
52W Low
$417.74
Fwd P/E
37.04
Mean Target
$572.68
Technical Score (1D)
14
SELL
News Sentiment
83
BULLISH
Intuitive Surgical (ISRG) announced a wave of innovations for its da Vinci 5 platform and supporting ecosystem, including enhanced product security, reliability, and extended-use instruments, aiming to improve user experience. These developments follow a strong Q1 performance, with 17% procedure growth and a 23% revenue increase, signaling continued operational momentum. However, recent analyst sentiment shows a mixed outlook; Goldman Sachs adjusted its price target to $558 from $621 while maintaining a Buy rating, and Bank of America lowered its target to $520 from $650, also reiterating a Buy. These target reductions, despite strong operational results, reflect a reassessment of medtech valuations influenced by inflation and sector-specific concerns. Investors will be watching for regulatory clearance on new features like mobile login and advanced targeting, as well as ongoing procedure growth and revenue trends in the upcoming quarters to gauge the impact of these innovations and analyst sentiment shifts.
Earnings Summary
Intuitive Surgical is a prominent medical technology company specializing in minimally invasive surgical solutions, most notably its da Vinci Surgical System, which enhances surgical precision. Operating within the Healthcare sector, specifically the Medical Instruments & Supplies industry, the company's offerings extend to diagnostic tools like the Ion endoluminal system, complemented by extensive training, service, and digital support for healthcare providers globally. In its most recent reported quarters, ISRG demonstrated a pattern of exceeding earnings per share estimates. For Q1 2026, the company reported an actual EPS of $2.50 against an estimate of $2.11, and for Q4 2025, actual EPS was $2.53 versus an estimate of $2.30. Revenue performance also showed strength, with Q1 2026 revenue at $2.77 billion exceeding the estimate of $2.62 billion, and Q4 2025 revenue at $2.87 billion surpassing the estimate of $2.80 billion. This indicates a positive trend in both earnings and revenue beats in the latest periods. Historically, ISRG has shown a consistent year-over-year growth trajectory, often surpassing analyst expectations for both earnings and revenue. For instance, in Q1 2026, revenue grew significantly year-over-year, and the company has a track record of beating estimates in multiple consecutive quarters, suggesting operational efficiency and strong market demand for its robotic surgical systems. Recent news highlights ISRG's recognition in the agentic AI sector, positioning it for potential future growth, although this is juxtaposed with broader market pressures affecting medical device companies, leading to some stocks trading near two-year lows. Despite these sector-wide headwinds and current trading ranges, ISRG reported a strong Q1 2026 with a 23% year-on-year revenue increase, driven by system installations and rising procedure volumes, reinforcing its market dominance in surgical robotics. Investors will be watching for ISRG's ability to sustain its robust financial growth and capitalize on the expanding surgical robotics market in the upcoming quarters, particularly observing how it navigates broader market sentiment and potential sector-wide challenges.

EPS

EstBeatMiss
$1.61$1.87$2.13$2.39$2.65Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$2.50 - -
Q1'26$2.11$2.50+18.7%
Q4'25$2.30$2.53+9.8%
Q3'25$1.99$2.40+20.7%
Q2'25$1.92$2.19+14.1%
Q1'25$1.73$1.81+4.4%

Revenue

EstBeatMiss
$2.2B$2.4B$2.6B$2.8B$3.0BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$2.9B - -
Q1'26$2.6B$2.8B+5.8%
Q4'25$2.8B$2.9B+2.4%
Q3'25 - $2.5B -
Q2'25 - $2.4B -
Q1'25 - $2.3B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

ISRG Stock Snapshot

ISRG is currently trading at $419.95, giving Intuitive Surgical, Inc. a market cap of 154.51B and a P/E ratio of 51.9. Today's range spans $414.30–$439.20, with shares opening at $432.22 and moving up $1.40 (0.3%) from the prior close. DailyIQ's technical score sits at 14/100 (SELL) with a news sentiment reading of 83/100.

Over the past year ISRG has traded between $417.74 and $603.88 - the current price is +0.5% off the 52-week low and -30.5% from the high. 42 analysts cover the stock with a Buy consensus and a mean 12-month target of $572.68 (range $378.00–$750.00), implying upside of +36.4%.

ISRG is showing a SELL signal (14/100) with bullish sentiment (83/100). Price: $419.95 (near 52-week lows within $417.74–$603.88). (P/E: 51.9) At 154.51B in Healthcare market cap, a bearish technical read accompanied by negative sentiment often marks the beginning of an earnings revision cycle downward - active managers trim before the revisions become consensus, compounding the selling pressure.

Analyst coverage for ISRG becomes a double-edged factor in a SELL phase: at 154.51B in Healthcare market cap, active coverage is high enough that downgrade risk is real and impactful. The 14/100 technical reading and bullish sentiment (83/100) at $419.95 (near 52-week lows) place the stock in the zone where one or two high-profile estimate cuts can convert a grinding decline into a sharper re-rating — the $417.74–$603.88 range establishes where that repricing lands.